131 related articles for article (PubMed ID: 9612845)
1. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
[TBL] [Abstract][Full Text] [Related]
2. Interaction between carbamazepine and bromperidol.
Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Furukori H; Kaneko S; Inoue Y
Eur J Clin Pharmacol; 1997; 52(3):219-22. PubMed ID: 9218929
[TBL] [Abstract][Full Text] [Related]
3. No interaction between desipramine and bromperidol.
Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y
Prog Neuropsychopharmacol Biol Psychiatry; 1996 Oct; 20(7):1265-71. PubMed ID: 8938825
[TBL] [Abstract][Full Text] [Related]
4. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S; Otani K
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):575-8. PubMed ID: 11999910
[TBL] [Abstract][Full Text] [Related]
5. Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite.
Suzuki A; Otani K; Mihara K; Yasui N; Kondo T; Tokinaga N; Furukori H; Kaneko S; Inoue Y; Hayashi K
Psychopharmacology (Berl); 1998 Feb; 135(4):333-7. PubMed ID: 9539256
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine.
Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y; Shibata M; Ikeda K
Ther Drug Monit; 1997 Jun; 19(3):261-4. PubMed ID: 9200764
[TBL] [Abstract][Full Text] [Related]
7. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
Furukori H
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806
[TBL] [Abstract][Full Text] [Related]
8. Poor reliability of therapeutic drug monitoring data for haloperidol and bromperidol using enzyme immunoassay.
Yasui-Furukori N; Furukori H; Saito M; Inoue Y; Kaneko S; Tateishi T
Ther Drug Monit; 2003 Dec; 25(6):709-14. PubMed ID: 14639057
[TBL] [Abstract][Full Text] [Related]
9. Prolactin response to bromperidol treatment in schizophrenic patients.
Yasui N; Kondo T; Otani K; Ishida M; Mihara K; Suzuki A; Kaneko S; Inoue Y
Pharmacol Toxicol; 1998 Mar; 82(3):153-6. PubMed ID: 9553995
[TBL] [Abstract][Full Text] [Related]
10. No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol.
Mihara K; Otani K; Yasui N; Ishida M; Kondo T; Suzuki A; Furukori H; Nagashima U; Kaneko S; Inoue Y
Ther Drug Monit; 1999 Jun; 21(3):297-300. PubMed ID: 10365640
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of haloperidol and bromperidol and their reduced metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography.
Yasui-Furukori N; Inoue Y; Chiba M; Tateishi T
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 805(1):175-80. PubMed ID: 15113555
[TBL] [Abstract][Full Text] [Related]
12. Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol.
Yasui-Furukori N; Saito M; Furukori H; Inoue Y; Someya T; Kaneko S; Tateishi T
Ther Drug Monit; 2004 Jun; 26(3):336-41. PubMed ID: 15167638
[TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; De Vries R; Kaneko S
J Clin Pharmacol; 2002 Oct; 42(10):1083-8. PubMed ID: 12362921
[TBL] [Abstract][Full Text] [Related]
14. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K
Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913
[TBL] [Abstract][Full Text] [Related]
15. No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite.
Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Kaneko S; Inoue Y; Shibata M; Ikeda K
Ther Drug Monit; 1997 Apr; 19(2):165-8. PubMed ID: 9108644
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
Nakamura A; Mihara K; Nemoto K; Nagai G; Kagawa S; Suzuki T; Kondo T
Ther Drug Monit; 2014 Dec; 36(6):815-8. PubMed ID: 24739668
[TBL] [Abstract][Full Text] [Related]
17. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
Mihara K; Suzuki A; Kondo T; Yasui N; Furukori H; Nagashima U; Ono S; Kaneko S; Otani K; Inoue Y
Ther Drug Monit; 2000 Jun; 22(3):245-9. PubMed ID: 10850389
[TBL] [Abstract][Full Text] [Related]
18. Prediction of haloperidol steady-state levels in plasma after a single test dose.
Javaid JI; Janicak PG; Sharma RP; Leach AM; Davis JM; Wang Z
J Clin Psychopharmacol; 1996 Feb; 16(1):45-50. PubMed ID: 8834418
[TBL] [Abstract][Full Text] [Related]
19. The characteristics of side-effects of bromperidol in schizophrenic patients.
Yasui-Furukori N; Kondo T; Ishida M; Tanaka O; Mihara K; Kaneko S; Otani K
Psychiatry Clin Neurosci; 2002 Feb; 56(1):103-6. PubMed ID: 11929578
[TBL] [Abstract][Full Text] [Related]
20. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
Mihara K; Suzuki A; Kondo T; Yasui N; Furukori H; Nagashima U; Otani K; Kaneko S; Inoue Y
Clin Pharmacol Ther; 1999 Mar; 65(3):291-4. PubMed ID: 10096261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
